Global Pediatric Development of Drugs, Biologics, and Medical Devices (e-book)

This book takes a comprehensive look at global regulations, guidance, and incentives for the development of products for the pediatric population.

Table of Contents

Section I: General
Chapter 1 Global Regulatory Initiatives

Section II: North America
Chapter 2 Regulations, Pediatric Study Plan, and Product Development—US
Chapter 3 Rare Diseases—US
Chapter 4 Medical Device Development—US
Chapter 5 Drug Regulations—Canada

Section III: LATAM
Chapter 6 Regulatory Initiatives—Latin America and the Caribbean

Section IV: European Union and Europe
Chapter 7 Paediatric Regulation and the Paediatric Investigation Plan—EU
Chapter 8 Regulatory Requirements—UK
Chapter 9 Regulatory Requirements—Switzerland

Section V: Asia Pacific
Chapter 10 Drug Development—Japan
Chapter 11 Regulations—Australia and New Zealand
Chapter 12 Regulations—China
Chapter 13 Drug Development—India

Section VI: Rest of the World
Chapter 14 Drug and Device Requirements—Rest of the World (RoW)

Jocelyn Jennings, MS, RAC-US, RAC-Drugs, RAC-Devices, and Linda McBride, RPh, RAC, editors

Contributing Authors


About the Book

Available formats: print and e-book

Global Pediatric Development of Drugs, Biologics, and Medical Devices takes an in-depth look at creating and implementing a global regulatory strategy for bringing pediatric drug products and pediatric medical devices to the healthcare market. This comprehensive resource will help you gain insight into the pediatric study plan (PSP) and pediatric investigation plan (PIP). Chapters cover pediatric regulations, regulatory requirements, tools, incentives, and pathways for developing products for the pediatric population.

Global Pediatric Development of Drugs, Biologics, and Medical Devices describes various regulatory initiatives that have been instrumental in increasing the availability pediatric drug products and pediatric medical devices, including global collaboration and harmonization initiatives on the part of regulatory authorities.

Global Pediatric Development of Drugs, Biologics, and Medical Devices aims to facilitate strategic discussions, to foster collaboration on pediatric plan development, and to progress the availability of new therapies to prevent, diagnose, and treat pediatric diseases worldwide.

The authors cover the global pediatric requirements for the major markets, including the US, EU, Switzerland, UK, Canada, Australia, Japan, and China, in addition to India, the Middle East, and Latin America. Regulatory professionals at all levels employed in the industry, academia, and health authorities will benefit from this comprehensive look at pediatric regulations.


Who will benefit from this book?

Different aspects of this book serve as great resources for regulatory professionals at all levels of RAPS Regulatory Competency Framework. Information provided in the individual chapters for a specific country/region will serve well those regulatory professionals at Levels 1 and 2 of the framework who are building their foundational knowledge of the laws, regulations, and guidances in their assigned country/region. Further, the global details provided in the book are a great resource for more senior regulatory professionals at Levels 3 and 4 who are responsible for global strategy development.


Purchasing Options

This book can be purchased in the following formats:

This book can also be purchased as part of the following bundles:


Published by RAPS © 2021. Paperback. 186 pages. ISBN (print): 978-1-947493-73-5. ISBN (digital): 978-1-947493-74-2.

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.